Detection of clonally related Escherichia coli isolates producing different CMY β-lactamases from a cystic fibrosis patient

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 5, 2013, Pages 1032-1035

  Crémet, Lise ^a,b   Caroff, Nathalie ^b   Giraudeau, Cécile ^a   Reynaud, Alain ^a,b   Caillon, Jocelyne ^a,b   Corvec, Stéphane ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Adaptive process; Expanded spectrum cephalosporinases; Hypermutators; Mucoidy

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CMY 2; BETA LACTAMASE CMY 94; BETA LACTAMASE CMY 95; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; IMIPENEM; OUTER MEMBRANE PROTEIN F; PORIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

AIRWAY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BIOFILM; CLONAL VARIATION; CYSTIC FIBROSIS; DIALYSIS CATHETER; ENZYME SYNTHESIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GENE FREQUENCY; GENE MUTATION; GROWTH RATE; HUMAN; LUNG TRANSPLANTATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; URINE;

ADAPTATION, BIOLOGICAL; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CLUSTER ANALYSIS; CYSTIC FIBROSIS; ENVIRONMENTAL MICROBIOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; VIRULENCE FACTORS;

EID: 84877111063     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks520     Document Type: Article

References (20)

1. Gangell C, Gard S, Douglas T et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 2011; 53: 425-32.
2. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299-323.
3. Ionescu M, Belkin S. Overproduction of exopolysaccharides by an Escherichia coli K-12 rpoS mutant in response to osmotic stress. Appl Environ Microbiol 2009; 75: 483-92.
4. Wang D, Calla B, Vimolmangkang S et al. The orphan gene ybjN conveys pleiotropic effects on multicellular behavior and survival of Escherichia coli. PLoS ONE 2011; 6: e25293.
5. Denamur E, Bonacorsi S, Giraud A et al. High frequency of mutator strains among human uropathogenic Escherichia coli isolates. J Bacteriol 2002; 184: 605-9.
6. Galan JC, Tato M, Baquero MR et al. Fosfomycin and rifampin disk diffusion tests for detection of Escherichia coli mutator strains. J Clin Microbiol 2004; 42: 4310-2.
7. Crémet L, Caroff N, Giraudeau C et al. Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC β-lactamase in a French hospital. Antimicrob Agents Chemother 2010; 54: 2216-8.
8. Corvec S, Crémet L, Leprince C et al. Epidemiology of Escherichia coli clinical isolates producing AmpC plasmidic β-lactamase during a 5-year period in a French teaching hospital. Diagn Microbiol Infect Dis 2010; 67: 277-81.
9. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. 2011. http://www.eucast.org (28 December 2012, date last accessed).
10. Crémet L, Corvec S, Bémer P et al. Orthopaedic-implant infections by Escherichia coli: molecular and phenotypic analysis of the causative strains. J Infect 2012; 64: 169-75.
11. Caso M, Casciaro R, Pessano S et al. Lung exacerbation in a cystic fibrosis patient caused by a multiresistant extended-spectrum β-lactamase (ESBL)-producing strain of Escherichia coli. J Cystic Fibrosis 2008; 7: S24.
12. Platell JL, Trott DJ, Johnson JR et al. Prominence of an O75 clonal group (clonal complex 14) among non-ST131 fluoroquinolone-resistant Escherichia coli causing extraintestinal infections in humans and dogs in Australia. Antimicrob Agents Chemother 2012; 56: 3898-904.
13. Ferenci T. Maintaining a healthy SPANC balance through regulatory and mutational adaptation. Mol Microbiol 2005; 57: 1-8.
14. Barlow M, Hall BG. Origin and evolution of the AmpC β-lactamases of Citrobacter freundii. Antimicrob Agents Chemother 2002; 46: 1190-8.
15. Rodriguez-Bano J, Miro E, Villar M et al. Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect 2012; 64: 176-83.
16. Doi Y, Paterson DL, Adams-Haduch JM et al. Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase. Antimicrob Agents Chemother 2009; 53: 3159-61.
17. Kotsakis SD, Papagiannitsis CC, Tzelepi E et al. Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. Antimicrob Agents Chemother 2009; 53: 3520-3.
18. Hentschke M, Kotsakis SD, Wolters M et al. CMY-42, a novel plasmid-mediated CMY-2 variant AmpC β-lactamase. Microb Drug Resist 2011; 17: 165-9.
19. Barnaud G, Benzerara Y, Gravisse J et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother 2004; 48: 1040-2.
20. Bogaerts P, Rodriguez-Villalobos H, Bauraing C et al. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered at two Belgian hospitals. Pathol Biol (Paris) 2010; 58: 78-83.